modelCefprozil
Extends from Pharmacolibrary.Drugs.ATC.J.J01DC10.
Information
| name: | Cefprozil | |
| ATC code: | J01DC10 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.23 | L |
| clearance: | 3.4 | L/h |
| other parameters in model implementation | ||
Cefprozil is a second-generation cephalosporin antibiotic, used to treat a variety of bacterial infections such as pharyngitis, tonsillitis, otitis media, skin and soft tissue infections, and respiratory tract infections. It is currently an approved antibiotic in various countries and is administered primarily via the oral route.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers, both genders, after a single oral dose under fasting conditions.
References
Bathini, L, et al., & Garg, AX (2019). Clinical Outcomes of Failing to Dose-Reduce Cephalosporin Antibiotics in Older Adults with CKD. Clinical journal of the American Society of Nephrology : CJASN 14(2) 197–205. DOI:10.2215/CJN.10710918 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30630861
Kays, MB, et al., & Miles, DO (1999). In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri. Pharmacotherapy 19(11) 1308–1314. DOI:10.1592/phco.19.16.1308.30869 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10555936
Pichichero, ME, et al., & Nicolau, DP (2008). Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatric drugs 10(6) 391–397. DOI:10.2165/0148581-200810060-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18998749
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)